World's Best Scientists 2026 revealed!
Aimery de Gramont

Aimery de Gramont

D-Index & Metrics

Medicine

D-Index
73
Citations
35066
World Ranking
19532
National Ranking
659

Aimery de Gramont publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Aimery de Gramont sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 385 publications — 35th percentile

35% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Aimery de Gramont D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Aimery de Gramont sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 73 D-Index — 3rd percentile

3% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Aimery de Gramont is affiliated with Grenoble Alpes University in France and has made significant contributions to the field of medicine, focusing primarily on oncology. Their research encompasses various aspects of cancer treatment and associated diagnostics, with a strong emphasis on colorectal and gastric cancers.

Their scholarly output features numerous publications in respected venues. Frequent publication outlets include:

  • Journal of Clinical Oncology
  • Annals of Oncology
  • European Journal of Cancer
  • JNCI Journal of the National Cancer Institute
  • UNC Libraries

Aimery de Gramont's recent papers reflect ongoing clinical and translational research in colorectal cancer. Among these are:

  • FOLFIRI Followed by FOLFOX6 or the Reverse Sequence in Advanced Colorectal Cancer: A Randomized GERCOR Study, 2023, Journal of Clinical Oncology
  • Microsatellite Instability in Patients With Stage III Colon Cancer Receiving Fluoropyrimidine With or Without Oxaliplatin: An ACCENT Pooled Analysis of 12 Adjuvant Trials, 2020, Journal of Clinical Oncology
  • Metastatic colorectal cancer: Advances in the folate-fluoropyrimidine chemotherapy backbone, 2021, Cancer Treatment Reviews
  • Prognostic Value and Relation with Adjuvant Treatment Duration of ctDNA in Stage III Colon Cancer: a Post Hoc Analysis of the PRODIGE-GERCOR IDEA-France Trial, 2021, Clinical Cancer Research
  • Sex and Adverse Events of Adjuvant Chemotherapy in Colon Cancer: An Analysis of 34,640 Patients in the ACCENT Database, 2020, JNCI Journal of the National Cancer Institute

Frequent co-authors collaborating with Aimery de Gramont include:

  • Qian Shi
  • Takayuki Yoshino
  • Thierry André
  • Benoist Chibaudel
  • John Zalcberg

Their research covers major topics within oncology, particularly:

  • Colorectal Cancer Treatments and Studies
  • Gastric Cancer Management and Outcomes
  • Genetic factors in colorectal cancer
  • Colorectal Cancer Surgical Treatments
  • Lung Cancer Treatments and Mutations
  • Cancer Treatment and Pharmacology
  • Cancer Genomics and Diagnostics

Main areas of study reflect a broad approach to cancer research with primary focus areas including:

  • Oncology
  • Pulmonary and Respiratory Medicine
  • Pathology and Forensic Medicine
  • Surgery
  • Cancer Research

Best Publications

  • Oxaliplatin, Fluorouracil, and Leucovorin as Adjuvant Treatment for Colon Cancer

    Thierry Andre;Corrado Boni;Lamia Mounedji-Boudiaf;Matilde Navarro

  • FOLFIRI Followed by FOLFOX6 or the Reverse Sequence in Advanced Colorectal Cancer: A Randomized GERCOR Study

    Christophe Tournigand;Thierry André;Emmanuel Achille;Gérard Lledo

  • Improved Overall Survival With Oxaliplatin, Fluorouracil, and Leucovorin As Adjuvant Treatment in Stage II or III Colon Cancer in the MOSAIC Trial

    Thierry Andre;Corrado Boni;Matilde Navarro;Josep Tabernero

  • OPTIMOX1: A Randomized Study of FOLFOX4 or FOLFOX7 With Oxaliplatin in a Stop-and-Go Fashion in Advanced Colorectal Cancer—A GERCOR Study

    Christophe Tournigand;Andres Cervantes;Arie Figer;Gérard Lledo

  • Disease-Free Survival Versus Overall Survival As a Primary End Point for Adjuvant Colon Cancer Studies: Individual Patient Data From 20,898 Patients on 18 Randomized Trials

    Daniel J. Sargent;Harry S. Wieand;Daniel G. Haller;Richard Gray

  • Evidence for Cure by Adjuvant Therapy in Colon Cancer: Observations Based on Individual Patient Data From 20,898 Patients on 18 Randomized Trials

    Daniel Sargent;Alberto Sobrero;Axel Grothey;Michael J. O'Connell

  • Paroxysmal nocturnal haemoglobinuria: long-term follow-up and prognostic factors

    Gérard Socié;Jean-Yves Mary;Aimery de Gramont;Bernard Rio

  • Adjuvant Fluorouracil, Leucovorin, and Oxaliplatin in Stage II to III Colon Cancer: Updated 10-Year Survival and Outcomes According to BRAF Mutation and Mismatch Repair Status of the MOSAIC Study

    Thierry André;Armand De Gramont;Dewi Vernerey;Benoist Chibaudel

  • Prognosis of patients with peritoneal metastatic colorectal cancer given systemic therapy: an analysis of individual patient data from prospective randomised trials from the Analysis and Research in Cancers of the Digestive System (ARCAD) database

    Jan Franko;Qian Shi;Jeffrey P Meyers;Timothy S Maughan

  • Impact of Chemoradiotherapy After Disease Control With Chemotherapy in Locally Advanced Pancreatic Adenocarcinoma in GERCOR Phase II and III Studies

    Florence Huguet;Thierry André;Pascal Hammel;Pascal Artru

  • The Oncosurgery Approach to Managing Liver Metastases from Colorectal Cancer: A Multidisciplinary International Consensus

    René Adam;Aimery De Gramont;Joan Figueras;Ashley Guthrie

  • Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial

    Aimery de Gramont;Eric Van Cutsem;Hans Joachim Schmoll;Josep Tabernero

  • Managing synchronous liver metastases from colorectal cancer: a multidisciplinary international consensus.

    René Adam;Aimery de Gramont;Joan Figueras;Norihiro Kokudo

  • Pooled Analysis of Safety and Efficacy of Oxaliplatin Plus Fluorouracil/Leucovorin Administered Bimonthly in Elderly Patients With Colorectal Cancer

    Richard M. Goldberg;Isabelle Tabah-Fisch;Harry Bleiberg;Aimery de Gramont

  • Can Chemotherapy Be Discontinued in Unresectable Metastatic Colorectal Cancer? The GERCOR OPTIMOX2 Study

    Benoist Chibaudel;Frédérique Maindrault-Goebel;Gérard Lledo;Laurent Mineur

  • Adjuvant Therapy With Fluorouracil and Oxaliplatin in Stage II and Elderly Patients (between ages 70 and 75 years) With Colon Cancer: Subgroup Analyses of the Multicenter International Study of Oxaliplatin, Fluorouracil, and Leucovorin in the Adjuvant Treatment of Colon Cancer Trial

    Christophe Tournigand;Thierry André;Franck Bonnetain;Benoist Chibaudel

  • Treatment of colorectal cancer in older patients: International Society of Geriatric Oncology (SIOG) consensus recommendations 2013

    Demetris Papamichael;R. A. Audisio;B. Glimelius;A. de Gramont

  • Biomarkers and surrogate end points—the challenge of statistical validation

    Marc Buyse;Daniel J. Sargent;Axel Grothey;Alastair Matheson

  • Multicenter Phase II Study of Bimonthly High-Dose Leucovorin, Fluorouracil Infusion, and Oxaliplatin for Metastatic Colorectal Cancer Resistant to the Same Leucovorin and Fluorouracil Regimen

    Thierry André;Mohamed A. Bensmaine;Christophe Louvet;Eric François

  • Phase II Trial of Cetuximab in Combination With Fluorouracil, Leucovorin, and Oxaliplatin in the First-Line Treatment of Metastatic Colorectal Cancer

    Josep Tabernero;Eric Van Cutsem;Eduardo Díaz-Rubio;Andrés Cervantes

Frequent Co-Authors

Thierry André
Thierry André Université Paris Cité
Richard M. Goldberg
Richard M. Goldberg West Virginia University
Axel Grothey
Axel Grothey University of Tennessee at Knoxville
Josep Tabernero
Josep Tabernero Vall d´Hebron Institute of Oncology
Leonard Saltz
Leonard Saltz Memorial Sloan Kettering Cancer Center
Julien Taieb
Julien Taieb Université Paris Cité
John R. Zalcberg
John R. Zalcberg Monash University
Marc Buyse
Marc Buyse Hasselt University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Pursuing a career in medicine doesn't always require the traditional path of attending medical school. There are various online degree options that can prepare you for rewarding roles within the healthcare sector. For those interested in healthcare leadership, exploring online mha programs affordable can provide a cost-effective route to management positions.

If you’re aiming to advance your nursing credentials, consider enrolling in one of the cheap online dnp programs. These programs can open doors to advanced clinical or academic positions while offering the flexibility of online study.

Pharmacy is another growing field, and several online pharmacist programs now make it more accessible than ever to earn a recognized qualification from home.

For those interested in the intersection of healthcare and technology, earning a bachelor of health information management online can lead to a career managing the vital flow of health data in medical organizations.

These online pathways offer flexibility, affordability, and opportunities to enter or advance in healthcare without following the traditional physician track.

Best Scientists Citing Aimery de Gramont

Trending Scientists

Recently Published Articles